1stOncology™: Cancer Intelligence Service – Page 14408 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2019 Financial Results

On July 23, 2019 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that the Company will host a webcast conference call to report its second quarter 2019 financial results and provide an update on the company’s business and outlook on Tuesday, August 6, 2019 at 4:30 p.m. (ET) after closing of the market (Press release, PTC Therapeutics, JUL 23, 2019, https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-second-quarter-2019-financial-results-300888784.html [SID1234537687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 6594813. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company’s website for two weeks.

Bruker Announces Date and Time of Second Quarter 2019 Earnings Release and Webcast

On July 23, 2019 Bruker Corporation (Nasdaq: BRKR) reported it will report second quarter 2019 financial results on Thursday, August 1, 2019, after the market closes (Press release, Bruker, JUL 23, 2019, View Source [SID1234537686]). The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends.

To listen to the webcast, investors can go to View Source and click on the "Earnings Webcast" hyperlink in the "Latest Results" section. A slide presentation will be referenced during the webcast and will be posted to the company’s website shortly before the webcast begins.

Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international), and referencing "Bruker’s Second Quarter 2019 Earnings Conference Call".

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit View Source and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call on August 1.

A telephone replay of the conference call will be available by dialing 1-877-344-7529 (U.S. toll free) or +1-412-317-0088 (international) and entering conference number: 10133865. The replay will be available beginning one hour after the end of the conference call through September 1, 2019.

For Further Information:

Miroslava Minkova

Director, Investor Relations & Corporate Development

Tel: +1 (978) 663-3660, ext. 1479

Email: [email protected]

Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call

On July 23, 2019 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday, August 6 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call (Press release, Halozyme, JUL 23, 2019, View Source [SID1234537685]). On the same date, Halozyme will release financial results for the second quarter ended June 30, 2019 following the close of trading.

The call will be webcast live through the "Investors" section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit the Investors page of www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. The live call may be accessed by dialing (877) 824-0907 (domestic callers) or (647) 689-5655 (international callers). A telephone replay will be available after the call by dialing (800) 585-8367 (domestic callers) or (416) 621-4642 (international callers) using replay ID number 5549627.

Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019

On July 23, 2019 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that it will report its 2019 second quarter financial results on Tuesday, August 6, 2019, after the close of the financial markets (Press release, Jazz Pharmaceuticals, JUL 23, 2019, View Source [SID1234537684]). Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2019 financial results and provide a business and financial update.

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least one week.

Audio webcast/conference call:
U.S. Dial-In Number: +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 5590569

A replay of the conference call will be available through August 13, 2019 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number: +1 404 537 3406
Passcode: 5590569

Immix Receives FDA Authorization to Expand Clinical Trial under US IND

On July 23, 2019 Immix Biopharma, Inc–a clinical-stage biopharmaceutical company developing next-generation cancer therapies–reported that it received a letter from the FDA authorizing it to proceed with expanding its phase 1b/2a clinical trial of IMX-110 to the United States under an IND (Press release, Immix Biopharma, JUL 23, 2019, View Source [SID1234537683]).

To-date, interim readouts from the phase 1b/2a trial in Australia are 100% CBR / DCR for all patients who completed the 5th cohort and at least 2 cycles, as scheduled – with the longest duration of response being 8-months of stable disease. No treatment-related serious adverse events have been observed to-date in any cohorts and dose escalation is continuing.

Immix’ Interim Medical Director and CEO Ilya Rachman, MD, PhD noted, "We were quite surprised and incredibly happy to see real clinical benefits of the drug at such an early stage in the trial. We are excited to explore the extent of this drug’s potential as we progress with dose escalation and approach the expected optimal therapeutic dose of the drug."

At present, Immix is finalizing selection of US clinical sites that will participate in this Phase 1b/2a multinational trial for advanced solid tumors.

Immix is also opening a call for investigator initiated studies where the company will provide its lead compound Imx-110 at no charge and is expanding its Series A financing to add more patients to the ongoing phase 1b/2a study.

About IMX-110
Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models — with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.